ADVENTRX Pharmaceuticals to Present at the 13th Annual BIO-Europe Partnering Conference

Search Blogs that Mention this News Release
Click this link to view linked Bookmarking Services
Click this link to view linked Blogging Services
ADVENTRX Pharmaceuticals to Present at the 13th Annual BIO-Europe Partnering Conference
    SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX), a biopharmaceutical research and development company
focused on commercializing proprietary product candidates for the treatment
of cancer and infectious diseases, announced today that Brian M. Culley,
ADVENTRX's chief business officer, is scheduled to present at the 13th
Annual BIO-Europe Partnering Conference on November 14th, 2007 at 11:30
a.m. Central European Time (5:30 a.m. Eastern Time). The conference takes
place in Hamburg, Germany at the CCH Congress Center, November 12 - 14,
2007.
    According to BIO-Europe, the 13th annual BIO-Europe event is the
world's largest dedicated biotechnology partnering conference. Almost two
thousand global decision-makers from biotechnology, pharma and finance
annually attend BIO-Europe to identify new business opportunities and
develop strategic relationships. BIO-Europe features the industry's most
advanced web-based partnering system, enabling delegates from all parts of
the biotechnology value-chain to quickly identify, engage and enter into
the strategic relationships that drive their business successfully forward.
    About ADVENTRX Pharmaceuticals
    ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. More information can be found
on the Company's web site at http://www.adventrx.com.
    Forward Looking Statements
    ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks and assumptions that, if they materialize or
do not prove to be accurate, could cause ADVENTRX's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. These risks and uncertainties include, but are
not limited to: the risk that ADVENTRX will be unable to raise sufficient
capital to fund the projects necessary to meet its anticipated or stated
goals and milestones; the ability to timely enroll subjects in and the
results of ADVENTRX's current and anticipated clinical trials; the
potential for ADVENTRX's product candidates to receive regulatory approval
for one or more indications on a timely basis or at all, and the uncertain
process of seeking regulatory approval; the market potential for ADVENTRX's
product candidates and ADVENTRX's ability to compete in those markets; and
other risks and uncertainties more fully described in ADVENTRX's press
releases and periodic filings with the Securities and Exchange Commission.
ADVENTRX's public filings with the Securities and Exchange Commission are
available at http://www.sec.gov.
    You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date when made. ADVENTRX does not
intend to update any forward-looking statement, including as set forth in
this press release, to reflect events or circumstances arising after the
date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
http://www.adventrx.com
CONTACT:
Investors, Ioana C. Hone of ADVENTRX
Pharmaceuticals, +1-858-552-0866